Abstracts tagged "radiography"

Abstract Number: 0160 • ACR Convergence 2021
Identifying Erosive Disease from Radiology Reports of Veterans with Inflammatory Arthritis with Natural Language Processing
Gopi Penmetsa¹, Jessica Walsh², Shaobo Pei³, Brian Sauer⁴, Kevin Douglas⁵, Jodi Walker⁵, Jerry Clewell⁶ and Bingjian Feng¹, ¹Salt Lake City Veteran Affairs and University of Utah Medical Centers, Salt Lake City, UT, ²Salt Lake City Veteran Affairs Medical Center (VAMC)/University of Utah Hospital, Salt Lake City, UT, ³VAMC, Salt Lake City, SLC, ⁴Veterans Affairs Medical Center, Salt Lake City, UT, ⁵AbbVie Inc., North Chicago, IL, ⁶Abbvie Inc, North Chicago, IL
Background/Purpose: The presence of erosive disease influences diagnosis, management, & prognosis in inflammatory arthritis (IA). Inflammatory arthritis research in large datasets is limited by a…
Abstract Number: 0168 • ACR Convergence 2021
A Crowdsourcing Approach to Develop Machine Learning Models to Quantify Radiographic Joint Damage in Rheumatoid Arthritis
Dongmei Sun¹, Robert Allaway², Jelai Wang¹, Verena Chung², Thomas Yu², Isaac Dimitrovsky³, Lars Ericson⁴, Yuanfang Guan⁵, Ariel Israel⁶, Hongyang Li⁵, Michael Mason⁷, Alex Olar⁸, Balint Pataki⁸, Stephanie Ledbetter¹, RA2 DREAM Challenge Community⁹, Gustavo Stolovitzky¹⁰, Justin Guinney², Percio Gulko¹¹, Mason Frazier¹, James Costello¹², Jake Chen¹ and S. Louis Bridges, Jr.¹³, ¹University of Alabama at Birmingham, Birmingham, AL, ²Sage Bionetworks, Seattle, WA, ³Self-employed, New York, NY, ⁴Catskills Research, Charlotte, NC, ⁵University of Michigan, Ann Arbor, MI, ⁶Hebrew University, Jerusalem, Israel, ⁷BMS, Seattle, WA, ⁸Eotvos Lorand University, Budapest, Hungary, ⁹RA2 DREAM Challenge Community, New York, NY, ¹⁰IBM, New York, NY, ¹¹Icahn School of Medicine at Mount Sinai, New York, NY, ¹²University of Colorado Anschutz Medical Campus, Denver, CO, ¹³Hospital for Special Surgery, New York, NY
Background/Purpose: Rheumatoid arthritis (RA) is a common chronic autoimmune disease characterized by inflammation of the synovium, leading to joint space narrowing and osseous erosions. The…
Abstract Number: 0748 • ACR Convergence 2020
Joint Space Narrowing Precedes Erosive Radiographic Damage in Patients with Rheumatoid Arthritis
Andreas Kerschbaumer¹, Gabriela Supp², Farideh Alasti¹, Josef Smolen² and Daniel Aletaha¹, ¹Division of Rheumatology, Department of Medicine III, Medical University of Vienna,, Vienna, Austria, ²Division of Rheumatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria
Background/Purpose: Rheumatoid arthritis (RA) is a chronic inflammatory disease characterized through symmetric polyarthritis leading to joint destruction over time in many patients. Radiographic damage is…
Abstract Number: 0754 • ACR Convergence 2020
The Association Between Continuous Decreases in Serum RF Titers and Radiographic Remission of Joint Damage in RA Patients Treated with Biological or Targeted Synthetic DMARDs
Takayoshi Owada¹, Ayae Tanaka², Hirokuni Hirata¹, Masafumi Arima³, Yasutsugu Fukushima¹ and Kazuhiro Kurasawa³, ¹Dokkyo Medical University Saitama Medical Center, Koshigaya, Saitama, Japan, ²Dokkyo Medical University, Shimotsuga-Gun, Japan, ³Dokkyo Medical University, Mibu, Shimotsugagun, Tochigi, Japan
Background/Purpose: Rheumatoid factors (RFs) are RA-related autoantibodies like anti-cyclic citrullinated peptide antibodies, and are used for classifying and diagnosing RA. In addition, positivity and high…
Abstract Number: 1049 • ACR Convergence 2020
Effects of Nintedanib in Patients with Progressive Fibrosing Autoimmune Disease-related Interstitial Lung Diseases (ILDs) in the INBUILD Trial: Subgroups by HRCT Pattern
Paul Dellaripa¹, Martin Aringer², Anna Maria Hoffmann-Vold³, Clive Kelly⁴, Shikha Mittoo⁵, Alexandra James⁶, Klaus Rohr⁶, Susanne Stowasser⁶ and Yoshikazu Inoue⁷, ¹Division of Rheumatology, Brigham and Women's Hospital, Boston, Massachusetts, USA, Boston, MA, ²Rheumatology, Medicine III, University Medical Center & Faculty of Medicine, TU Dresden, Dresden, Germany, Dresden, Germany, ³Department of Rheumatology, Oslo University Hospital, Oslo, Norway, Oslo, Norway, ⁴Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK, Newcastle upon Tyne, United Kingdom, ⁵University Health Network, Toronto, Ontario, Canada, Toronto, ON, Canada, ⁶Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, Ingelheim am Rhein, Germany, ⁷Clinical Research Center, National Hospital Organization Kinki-Chuo Chest Medical Center, Sakai City, Osaka, Japan, Sakai City, Osaka, Japan
Background/Purpose: In the INBUILD trial, nintedanib reduced the rate of decline in forced vital capacity (FVC) over 52 weeks compared with placebo in patients with…
Abstract Number: 1161 • ACR Convergence 2020
Perspectives of Radiologist Physicians in the Imaging of Chronic Nonbacterial Osteomyelitis
Farzana Nuruzzaman¹, Mingqian Huang², Christian Hedrich³, Hermann Girschick⁴, Julie Cherian⁵, T. Shawn Sato⁶, Karen Onel⁷, Polly Ferguson⁸ and Yongdong Zhao⁹, ¹Stony Brook Children's Hospital, Stony Brook, NY, ²Mount Sinai Hospital, 10003, NY, ³University of Liverpool, Liverpool, United Kingdom, ⁴Vivantes Children’s Hospital, Wuerzburg, Germany, ⁵Stony Brook Children�s Hospital, Stony Brook, NY, ⁶University of Iowa, Iowa City, ⁷Pediatric Rheumatology, Hospital for Special Surgery, New York, NY, ⁸University of Iowa Carver College of Medicine, Iowa City, IA, ⁹University of Washington, Seattle, WA
Background/Purpose: Radiological imaging is integral to the diagnosis of chronic nonbacterial osteomyelitis (CNO) and has been included as a central component in suggested diagnostic criteria…
Abstract Number: 1235 • ACR Convergence 2020
Radiographic Progression of Structural Joint Damage over 5 Years of Baricitinib Treatment in Patients with Rheumatoid Arthritis: Results from RA-BEYOND
Désirée van der Heijde¹, Cynthia E Kartman², Li Xie², Scott Beattie², Douglas Schlichting², Patrick Durez³, Yoshiya Tanaka⁴ and Roy Fleischmann⁵, ¹Leiden University Medical Center, Leiden, Netherlands, ²Eli Lilly and Company, Indianapolis, IN, ³Division of Rheumatology, Cliniques Universitaires Saint-Luc, Bruxelles, Belgium, ⁴The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan, ⁵Southwestern Medical Center, Metroplex Clinical Research Center, Dallas, TX
Background/Purpose: Baricitinib (BARI) is an oral, reversible and selective Janus kinase 1 and 2 inhibitor. Treatment with once-daily oral BARI resulted in low rates of…
Abstract Number: 1458 • ACR Convergence 2020
Slower Current Walking Speed Is Associated with Progression in Radiographic Knee Osteoarthritis: The Johnston County Osteoarthritis Project
Lindsey Duca¹, Liubov Arbeeva², Yvonne Golightly³, Louise Murphy⁴, Charles Helmick⁴ and Kamil Barbour⁵, ¹Centers for Disease Control and Prevention, Chamblee, GA, ²University of North Carolina at Chapel Hill Thurston Arthritis Research Center, Chapel Hill, NC, ³University of North Carolina at Chapel Hill Dept of Epidemiology, Chapel Hill, NC, ⁴Centers for Disease Control and Prevention, Atlanta, GA, ⁵CDC, Atlanta, GA
Background/Purpose: Poorer physical functioning as a single baseline measurement has been associated with increased risk of radiographic knee osteoarthritis (rKOA) progression, but it is unknown…
Abstract Number: 1487 • ACR Convergence 2020
Biclustering Reveals Potential Knee Osteoarthritis Phenotypes in Exploratory Analyses: Data from the Osteoarthritis Initiative
Amanda Nelson¹, Thomas Keefe², Todd Schwartz³, Richard Loeser¹, Yvonne Golightly⁴, Liubov Arbeeva¹ and J Marron², ¹University of North Carolina at Chapel Hill Thurston Arthritis Research Center, Chapel Hill, NC, ²University of North Carolina at Chapel Hill, Chapel Hill, NC, ³University of North Carolina at Chapel Hill Dept of Biostatistics, Chapel Hill, NC, ⁴University of North Carolina at Chapel Hill Dept of Epidemiology, Chapel Hill, NC
Background/Purpose: To utilize novel methodologies to explore subgroups within the OAI clinical data.Methods: From the OAI baseline dataset (n=4796 individuals with or at risk of…
Abstract Number: 1644 • ACR Convergence 2020
Radiographic Exclusionary Findings During Screening for Three Phase III Trials of Subcutaneous Tanezumab in Patients with Moderate to Severe Hip or Knee Osteoarthritis
Ali Guermazi¹, Frank Roemer², Andrew Kompel¹, Luis Diaz³, Michel Crema⁴, Mark Brown⁵, Anne Hickman⁵, Glenn Pixton⁶, Lars Viktrup⁷, Robert Fountaine⁵, Aimee Burr⁵, Sarah Sherlock⁵ and Christine West⁸, ¹Boston University School of Medicine, Boston, MA, ²Boston University School of Medicine, Boston, MA, and Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany, Erlangen, Germany, ³Boston Veteran Affairs Healthcare System, Boston, MA, ⁴Boston University School of Medicine, Paris, France, ⁵Pfizer Inc., Groton, CT, ⁶Pfizer Inc., Morrisville, NC, ⁷Eli Lilly and Company, Indianapolis, IN, ⁸Pfizer Inc, Groton, CT
Background/Purpose: Tanezumab is a nerve growth factor monoclonal antibody in development for osteoarthritis (OA). Following a clinical hold due to concerns around adverse joint events,…
Abstract Number: 1756 • ACR Convergence 2020
Comparable Long-Term Outcomes Among DAS28-ESR-based Remission Criteria and ACR/EULAR Definitions in Patients with Established Rheumatoid Arthritis
Felipe Julio Ramirez Garcia¹, Jose Inciarte-Mundo², Andrea Cuervo³, Raquel Celis⁴, Virginia Ruiz-Esquide⁴, Raul Castellanos-Moreira⁵, Andres Ponce⁴, Jose Gómez-Puerta⁶, Raimon Sanmartí⁶ and Juan Cañete⁷, ¹Arthritis Unit, Rheumatology Dpt, Hospital Clinic, Barcelona, Spain, Barcelona, Catalonia, Spain, ²Hospital Universitari Clínic de Barcelona, Barcelona, ³Hospital Clínic, Barcelona, Spain, ⁴Hospital Clinic, Barcelona, Spain, ⁵Hospital Clinic of Barcelona, Barcelona, Spain, ⁶Hospital Universitari Clínic de Barcelona, Barcelona, Catalonia, Spain, ⁷Arthritis Unit, Rheumatology Dpt, Hospital Clinic, Barcelona, Spain and IDIBAPS, Barcelona, Spain
Background/Purpose: To compare long-term clinical and radiographic outcomes among five sets of remission criteria [four clinical and one Ultrasound (US)-based] in a cohort of RA…
Abstract Number: 1895 • ACR Convergence 2020
Radiographic Progression in Patients with Axial Spondyloarthritis Under Treatment with TNF Inhibitors. Data from REGISPONSERBIO (Spanish Register of Biological Therapy in Spondyloarthritides)
Maria Llop¹, Mireia Moreno², Jordi Gratacós³, Victoria Navarro-Compán⁴, Eugenio De Miguel⁵, Pilar Font⁶, Teresa Clavaguera⁷, Luis Francisco Linares⁸, Beatriz Joven⁹ and Xavier Juanola¹⁰, ¹Hospital Universitari Parc Taulí I3PT, Sabadell, Catalonia, Spain, ²Hospital Universitari Parc Taulí I3PT, Sabadell, Spain, ³University Hospital Parc Tauli Sabadell, Barcelona, Spain, ⁴Hospital Universitario La Paz IdiPaz, Madrid, Pais Vasco, Spain, ⁵Rheumatology Department, Hospital Universitario La Paz, Madrid, Spain, ⁶Rheumatology Department, Reina Sofia University Hospital/ Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ University of Cordoba, Cordoba, Spain, Córdoba, Spain, ⁷Hospital Universitari Trueta, Girona, Spain, ⁸Hospital de la Arrixaca, Murcia, ⁹Hospital Universitario 12 de Octubre, Madrid, Spain, ¹⁰Rheumatology Service, University Hospital Bellvitge, IDIBELL, Barcelona, Spain, Barcelona, Spain
Background/Purpose: Clinical efficacy of TNF inhibitors (TNFi) in axial spondyloarthritis (axSpA) has been widely probed in randomized control trials. In clinical practice, some studies suggested…
Abstract Number: 1975 • ACR Convergence 2020
Predicting Bone Mineral Density of Lumbar Vertebrae by Assessing Plain Film with Deep Learning
Chen-I Hsieh¹, Chang-Fu Kuo¹, Shun Miao², Kang Zheng² and Le Lu², ¹Chang Gung Memorial Hospital, Taoyuan, Taiwan (Republic of China), ²PAII labs, Bethesda, MD
Background/Purpose: Osteoporosis is a silent disease characterized by a decrease in bone mineral density (BMD), causing bone fragility and increased risk of fracture. The most…
Abstract Number: 2016 • ACR Convergence 2020
Baseline Serum Biomarker Levels Predict Spinal Radiographic Progression in Ankylosing Spondylitis Patients on TNF Inhibitor Therapy
Judith Rademacher¹, Mark Siderius², Laura Gellert¹, Freke Wink³, Maryna Verba¹, Fiona Maas⁴, Lorraine M Tietz¹, Denis Poddubnyy⁵, Anneke Spoorenberg³ and Suzanne Arends³, ¹Charité Universitätsmedizin Berlin, Berlin, Germany, ²Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ³University Medical Centre Groningen and Medical centre Leeuwarden, Groningen, Netherlands, ⁴University medical Centre Groningen, Groningen, Netherlands, ⁵Charité – Universitätsmedizin Berlin, Berlin, Germany
Background/Purpose: Radiographic spinal progression determinates functional status and mobility in ankylosing spondylitis (AS) (Poddubnyy et al, 2018). Our objective was to analyze whether biomarker levels…
Abstract Number: 2017 • ACR Convergence 2020
Machine Learning Identifies an Association Between Pre-existing Radiographic Damage and Long-term Clinical Outcomes with Secukinumab Therapy in Patients with Psoriatic Arthritis
Philip Mease¹, Désirée van der Heijde², Bruce Kirkham³, Georg Schett⁴, Ana-Maria Orbai⁵, Christopher Ritchlin⁶, Joseph Merola⁷, Luminita Pricop⁸, Xuan Zhu⁹, DavidA James⁹ and Gregory Ligozio⁹, ¹Seattle Rheumatology Associates, P.L.L.C., Seattle, WA, ²Leiden University Medical Center, Leiden, Netherlands, ³Guy's & St Thomas' NHS Foundation Trust, London, United Kingdom, ⁴Friedrich-Alexander-Universität Erlangen- Nuremberg, Erlangen, Germany, ⁵Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁶Department of Medicine, University of Rochester Medical Center, Rochester, NY, ⁷Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, ⁸Novartis Pharmaceuticals Corporation, East Hanover, ⁹Novartis Pharmaceuticals Corporation, East Hanover, NJ
Background/Purpose: Assessment of radiographic joint damage extent and progression is important in clinical trials evaluating treatments for psoriatic arthritis (PsA). Joint damage in patients with…

« Previous Page
1
…
3
4
5
6
7
…
9
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].